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ABSTRACT
Topoisomerase IIa (topo IIa) is a nuclear enzyme
involved in several critical processes, including
chromosome replication, segregation and recom-
bination. Previously we have shown that chromo-
somal protein HMGB1 interacts with topo IIa, and
stimulates its catalytic activity. Here we show the
effect of HMGB1 on the activity of the human topo
IIa gene promoter in different cell lines. We demon-
strate that HMGB1, but not a mutant of HMGB1
incapable of DNA bending, up-regulates the activity
of the topo IIa promoter in human cells that lack
functional retinoblastoma protein pRb. Transient
over-expression of pRb in pRb-negative Saos-2
cells inhibits the ability of HMGB1 to activate the
topo IIa promoter. The involvement of HMGB1
and its close relative, HMGB2, in modulation of
activity of the topo IIa gene is further supported by
knock-down of HMGB1/2, as evidenced by signifi-
cantly decreased levels of topo IIa mRNA and
protein. Our experiments suggest a mechanism of
up-regulation of cellular expression of topo IIa by
HMGB1/2 in pRb-negative cells by modulation of
binding of transcription factor NF-Y to the topo IIa
promoter, and the results are discussed in the
framework of previously observed pRb-inactivation,
and increased levels of HMGB1/2 and topo IIa
in tumors.
INTRODUCTION
DNA topoisomerase II (topo II) is an essential and ubi-
quitous enzyme for proliferation of eukaryotic cells (1).
It can alter the topological state of DNA and untangle
DNA knots and catenanes (interlocked rings) via
ATP-dependent passing of an intact double helix through
a transient double-stranded break generated in a separate
DNA segment, followed by religation and enzyme
turnover (2). In mammalian cells, topo II exists in two
isoforms, a (170kDa) and b (180kDa), both having
similar primary structure and almost identical catalytic
properties, but diﬀering in their production during
the cell cycle (1,3). Topo II is the target of a number
of drugs currently used in the treatment of human malig-
nancies, such as etoposide, teniposide, doxorubicine and
mitoxantrone (3). These drugs (also termed topo II
poisons) can stabilize the covalent enzyme-associated
complexes and shift the DNA cleavage/religation equilib-
rium of the enzyme reaction toward the cleavage state,
converting biological intermediates of topo II activity
into lethal ones ultimately leading to triggering of pro-
grammed cell death pathways (1,3,4).
HMGB-type proteins are relatively abundant and
evolutionarily highly conserved non-histone chromatin-
associated proteins in mammals. There are three HMGB
variants in human and mice, HMGB1, HMGB2 and
HMGB3. While HMGB1-3 proteins are expressed
in early mice embryos, HMGB2 and HMGB3 are
down-regulated during embryonic development (5). The
abundant HMGB1 protein ( 1 molecule per 10–15
nucleosomes) is highly conserved among mammals, and
it continues to be ubiquitously expressed in adults.
HMGB1 and HMGB2 function in a number of funda-
mental cellular processes such as transcription, replica-
tion, DNA repair and recombination (5–8). HMGB1 is
associated with chromosomes in mitosis and due to its
extreme mobility in the cell the protein is continuously
exchanged between nucleus and cytoplasm [(8) and refs
therein]. HMGB1, but not HMGB2, also exhibits an
important extracellular function in mediation of inﬂam-
mation mechanisms, tumor growth and metastasis (6,8).
HMGB1, like HMGB2-3, has a tripartite domain organi-
zation, consisting of two DNA-binding domains, the
HMG-boxes A and B, and acidic C-terminal tails of vari-
able length. While the two HMG-boxes interact with
DNA (exhibiting a high aﬃnity for distorted DNA con-
formations (9–12), the C-tail usually decreases the aﬃnity
of the protein for DNA (5,7). Binding of HMGB1 to
DNA causes local distortions by bending/looping and
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acts weakly with a number of proteins, including tran-
scriptional factors, site-speciﬁc recombination and DNA
repair proteins (8). The importance of HMGB1 for life is
supported by the phenotype of the HMGB1 knockout
mice, which die 24h after birth due to hypoglycemia and
exhibit a defect in the transcriptional function of the
glucocorticoid receptor (15). Lack of HMGB1 in primary
mouse embryonic ﬁbroblasts correlates with higher rates
of DNA damage after UV irradiation, and the cytogenetic
analyses revealed high levels of aneuploidy and spontane-
ous chromosome aberrations, decreased activity of telo-
merase and shortening of telomere lengths, suggesting
that HMGB1 plays an important role in promoting geno-
mic stability (5,16).
Previously we have reported that HMGB1 could inter-
act with topo IIa and stimulate its enzymatic activity (11).
In the present study we studied an impact of over-
expression of HMGB1 and its close relative, HMGB2,
on the activity of human topo II  promoter. Using luci-
ferase gene reporter assay we have demonstrated that
HMGB1, but not a mutant of HMGB1 incapable of
DNA bending, up-regulated the activity of human topo
II  promoter in human cells that lack functional retino-
blastoma protein pRb. Transient over-expression of pRb
in Rb-minus cells inhibited the transactivation potential
of HMGB1 over the topo II  promoter. In agreement
with the above data, up-regulation of the topo II  pro-
moter by HMGB1/2 was very low in cells with functional
pRb. The involvement of HMGB1 and HMGB2 in
modulation of cellular activity of the topo II  gene was
also supported by silencing of HMGB1/2 expression by
plasmid-encoded speciﬁc shRNA resulting in diminished
expression of topo IIa. Our experiments allowed us to
propose a mechanism of HMGB1-mediated transactiva-
tion of the topo II  promoter by modulation of transcrip-
tional factor NF-Y binding to the promoter. The obtained
results are discussed in the framework of previously
observed increased levels of HMGB1 and topo IIa in
tumors (17).
MATERIALS AND METHODS
Plasmids
Each of the supercoiled DNA plasmids was isolated by
alkaline lysis method, followed by puriﬁcation by two
rounds of cesium chloride gradients or by the Qiagen
plasmid kits. All puriﬁed plasmids exhibited ratios
A260/A280 higher than 1.85.
Antibodies
Anti-HMGB1 or anti-HMGB2 (aﬃnity puriﬁed rabbit
polyclonal, BD Pharmingen), a-HMGB1 (monoclonal
IgG2a, clone #KS1, Stressgen), a-topo IIa (mouse mono-
clonal or rabbit polyclonal, Topogen), a-pRb (rabbit poly-
clonal C-15, Santa-Cruz), a-pan-actin (mouse
monoclonal, Dako), a-Flag (mouse monoclonal M2
clone, Sigma), a-NF-YB (rabbit polyclonal, a gift from
Roberto Mantovani, Italy) or from GeneSpin (PAb001,
Milano, Italy).
DNA circularization assay
T4 DNA ligase-mediated circularization was carried out
as described earlier (18) with the following modiﬁcations.
Brieﬂy, ligation was carried out at DNA concentration
of  1nM and the concentrations of HMGB1 protein
and peptides were 0.5–6mM. The DNA probe was a
gel-puriﬁed 123-bp AvaI DNA fragment (prepared by
AvaI digestion of the 123-bp DNA lather, BRL) that
was
32P-labeled at 50-ends by T4 DNA kinase and
[g-
32P]ATP (Amersham Biotech). Ligation reactions were
initiated by addition of 0.1U of T4 DNA ligase (Promega)
and were allowed to proceed at 308C for 30min. The
ligation products were then deproteinised, followed by
their resolution by electrophoresis on 5% polyacrylamide
gels in 0.5  TBE as detailed in (19). The amount of
monomer DNA circles was determined from quantitative
analyses of dried gels on a Molecular Dynamics Storm
PhosphorImager using the ImageQuant software.
Electrophoreic mobility shiftexperiments (EMSA)
The oligonucleotides for EMSA were derived from
human topo II  promoter (50 to 30): ICE1(WT)-F:CTA
GGAGCGAGTCAGGGATTGGCTGGTCTG; ICE1
(WT)-R: CAGACCAGCCAATCCCTGACTCGCTCCT
AG; ICE1(MUT)-F: CTAGGAGCGAGTCAGGGCTG
GACTGGTCTG; ICE1(MUT)-R: CAGACCAGTC
CAGCCCTGACTCGCTCCTAG; ICE2(WT)-F: CTAG
AAGGCAAGCTACGATTGGTTCTT; ICE2(WT)-R: A
AGAACCAATCGTAGCTTGCCTTCTA G-30; ICE2
(MUT)-F: CTAGAAGGCAAGCTACGCTGGATTCT
T-30; ICE2(MUT)-R: AAGAATCCAGCGTAGCTTGC
CTTCTAG-30; ICE3(WT)-F: CTAGCTCCCTAACCTG
ATTGGTTTATTCAAA-30; ICE3(WT)-R: TTTGAA
TAAACCAATCAGGTTAGGGAGCTAG-30; ICE3
(MUT)-F: CTAGCTCCCTAACCTGCTGGATTTATT
CAAA-30; ICE3(MUT)-R: TTTGAATAAATCCAGCA
GGTTAGGGAGCTAG-30.
The oligonucleotides were
32P-labeled at their 50-termini
by T4 DNA kinase and [g-
32P]ATP (Amersham Biotech)
and annealed with their complementary strands to
form blunt-ended DNA duplexes. Reaction mixtures
for EMSA contained control nuclear extract (5–10mg
of proteins) or extract pre-incubated with HMGB1 (wild-
type or F38A/F103A mutant, typically 1–4mM) and/or
His-pRb(wt) [0.1–0.4mg, puriﬁed from BL21(DE3)pLysS
Escherichia coli cells harboring the plasmid pRSET(his-
Rb); the plasmid was kindly provided by Ronen
Marmorstein from the Wistar Institute, Philadelphia,
USA], 1mg of poly (dI.dC) as a non-speciﬁc competitor,
and  3ngof
32P-labeled DNA duplexes in EMSA buﬀer
(20mM HEPES, pH 7.6, 4% Ficoll, 50mM KCl, 0.1%
Nonidet P-40, 0.2mM EDTA and 0.5mM DTT) in a
total volume of 20ml. DNA and proteins from nuclear
extract were pre-incubated on ice for 20min. Identity of
transcription factor NF-Y within the retarded DNA–pro-
tein complexes was veriﬁed by pre-incubation of the pro-
tein–DNA complexes with 0.5mg of polyclonal a-NF-YB
antibodies[kindlyprovidedbyRobertoMantovani,Dipar-
timento di Scienze Biomolecolari e Biotecnologie, Univer-
sita ` di Milano, Milano, Italy; (9)] at 308C for 20min.
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acrylamide gels in 0.5  TBE buﬀer at 200V for  2–3h
(48C). The gels were dried and the labeled DNA was ima-
gined by PhosporImager Storm (Molecular Probes).
Cloning ofHMGB1 plasmids
HMGB1 (residues 1–215), HMGB1 domain A (HMG-box
A, residues 1–88), HMGB1 domain B (HMG-box B, resi-
dues 85–180) and HMGB1 mutants were derived from
rat or human HMGB1 cDNAs (the amino-acid sequence
of the rat HMGB1 protein is identical to that of the
human HMGB1 protein). The DNA sequences coding
for the HMGB1 protein, mutants and domains were
inserted into BamHI and SalI sites of the vector pQE-
80L (Qiagen), which allows tightly regulated N-terminal
6  His-tagged protein expression in E. coli. Alanine muta-
genesis of intercalating residues F38, F103 or I122 of
isolated HMGB1 domains A or B, and mutagenesis of
F38/F103 (double mutant or F/F) of the full-length
HMGB1 was carried out by the protocol using ‘chimeras’
(S ˇ tros, unpublished results). The introduced mutations
were veriﬁed by dideoxi-sequencing of both strands. For
protein expression in E. coli, the HMGB1 and truncated
HMGB1 cDNAs were re-cloned into the pQE-80L vector
(His-tagged proteins). For transfections, the HMGB1
and HMGB2 cDNAs were cloned into the Flag-pcDNA3
or pcDNA3 vectors (20).
Cellculture
The human osteosarcoma Saos-2 cells (p53
 / , Rb
 / ), the
breast cancer MCF-7 cells (p53
+/+, Rb
+/+) and the non-
small lung carcinoma H1299 cells (p53
 / , Rb
+/+) were
grown in 1640 RPMI (Sigma). The 5637 cells (p53
 / ,
Rb
 / ), originally established from the primary bladder
carcinoma of a 68-year-old man, was purchased from
DSMZ (No: ACC 35). Stable Saos-2 derivatives in
which the expression of pRb was controlled by the tetra-
cykline regulated promoter were kindly obtained from
Liang Zhu [Department Developmental and Molecular
Biology, Albert Einstein College of Medicine, NY; (21)].
The pRb-inducible Saos-2 cells were grown in the presence
of 1mg/ml of tetracycline to prevent pRb expression. All
media were supplemented with 10% (v/v) heat-inactivated
fetal bovine serum, 2mM L-glutamine, 100U/ml penicil-
lin, 100mg/ml streptomycin, and the cells were grown in
5% C02 at 378C.
Celltransfections
Cells were detached by trypsine treatment at 80–90%
conﬂuence, and transfected with plasmids either by the
use of Amaxa Nucleofector II (Amaxa, Germany) or
Fugene HD (Roche). To select for stably transfected
cells, Geneticin (BRL) or Zeocin (Invitrogen) were
added following 48h of transfection.
shRNA-mediated gene silencing ofHMGB1 and HMGB2
Plasmid pcDNA-Zeo( )-U6 under the control of a
human U6 promoter was used to express two diﬀerent
short hairpin RNAs (shRNAs) that speciﬁcally cleave
HMGB1 (construct #A) and HMGB1/2 (construct #B)
mRNAs in human cells (the plasmids were kindly pro-
vided by Stephen Lippard, Dept. Chemistry, MIT,
Cambridge). The following hHMGB1 (#A: GGAGAAC
ATCCTGGCCTGT) or hHMGB2 (#B: AGTGAACACC
CTGGCCTAT) sequences were used to create DNA cas-
settes in pcDNA-Zeo( )-U6 vector expressing speciﬁc
shRNAs for silencing of HMGB1 or HMGB1/2 expres-
sion in human cells, respectively. Scrambled human
HMGB2 sequence (not related to any human sequence)
was used as a control (GAGAGGACAAGAGATGTA
TT). For the purpose of preparation of stably transfected
cells, the growth media contained 300mg/ml Zeocin
(Invitrogen) and the cells were selected for 2–3 weeks.
siRNA-mediated gene silencing of pRb
Speciﬁc siRNAs for knock-down of pRb in H1299 cells
were designed as reported in ref. (44). Rb-positive H1299
cells were transfected with 0.25mg of either a control
duplex siRNA [all sequences were 50-to-30; GGGCGUC
GAUCCUAACCGGdTdT (top) and CCGGUUAGGA
UCGACGCCCdTdT (low)] or a mixture of two Rb-spe-
ciﬁc siRNA duplexes [#1: GAUACCAGAUCAUGUCA
GAdTdT (top) and UCUGACAUGAUCUGGUAU
CdTdT (low); #2: CCCAGCAGUUCGAUAUCU
AdTdT (top) and UAGAUAUCGAACUGCUGG
GdTdT (low); Eurogentec S.A. (Lie ` ge)] using the
X-tremeGENE siRNA transfection reagent (Roche,
Mannheim) as recommended by the manufacturer. For
the luciferase gene reporter assays, the corresponding
siRNA duplexes were transiently co-transfected with plas-
mid pTIIa-617 and either plasmid pcDNA3 or plasmid
pcDNA-HMGB1 as detailed below.
Luciferase reporter gene assays
Transient transfections for luciferease gene reporter assays
were carried out in 24-well plates using Fugene HD
according to manufacturer instructions (Roche). When
using the Amaxa Nucleofector II (Amaxa, Germany),
transfections were carried out in six-well plates (2 10
5
cells/well) using the plasmid amounts as indicated below.
Transfection mixtures contained Flag-pcDNA3 expres-
sion vectors encoding full-length HMGB1 (residues
1–214), HMGB1-C (residues 1–179) or double-mutant
HMGB1 (F38A/F103A), and/or human wild-type pRb
[pBC-Rb(379–928)] and mutant pRb [pBC-Rb(379–928),
amino-acid 706 C!F]; [kindly provided by Pradip
Raychaudhuri, Department of Biochemistry, College of
Medicine, University of Illinois, Chicago; (22)], typically
0.5mg (Rb) and 2mg (HMGB1 or HMGB2) of the plasmid
DNA. The following reporter constructs (each 0.4mg)
were used: plasmid pGL3-Basic containing ﬁreﬂy
Photinus pyralis cDNA (Promega) linked with sequences
derived from human topo II  gene promoter: plasmid
pTIIa-617 containing either wild-type human topo II 
promoter or mutated promoter within the ICE2 sequence
[the promoter sequences were from bp  617 to +90
and the plasmids were kindly provided by Karin M.
Stowell, Institute of Molecular BioSciences, Palmerston
North, New Zealand; (23)]; or one of the plasmids
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containing varying lengths of the human topo II  pro-
moter as indicated [kindly provided by D. Parker Suttle,
Department of Pharmacology, College of Medicine,
University of Tennessee, Tennessee, USA; (24)].
Mutation of the ICE2 within the plasmid pTIIa-142 was
carried out by the QuickChange II Site-Directed
Mutagenesis Kit (Stratagene) using the following primers:
top, 50-GATATAAAAGGCAAGCTACGGTGGATTC
TTCTGGACGGAGACG-30; low, 50-CGTCTCCGTCC
AGAAGAATCCACCGTAGCTTGCCTTTTATATC-30
(the mutated ICE2 is highlighted). The introduced muta-
tions within the ICE2 (ATTGG mutated to GTGGA) of
the topo IIa promoter (plasmid pTIIa-142_ICE2 mut)
were conﬁrmed by dideoxy sequencing. In control lucifer-
ase assays, the topo IIa promoter-pGL3 constructs were
replaced by the empty vector pGL3-Basic. The equal
amount of plasmid DNAs in each transfection mixtures
was achieved by adding corresponding amounts of empty
(promoter-less) plasmid vectors to ﬁnal 3.6mg of the
transfection mixture when using Amaxa Nucleofector II
for transfection. The luciferase activity was measured
40–44h after transfection using a dual-luciferase reporter
assay system (Promega). Results are presented as changes
of transactivation of the topo II  promoter constructs rela-
tive to the original activity of these promoter constructs in
cells not transfected with plasmids expressing (HMGB or
pRb) proteins. In some luciferase reporter gene assays, the
pRL family Renilla luciferase control reporter vector
(0.4mg) with the cDNA encoding Renilla luciferase under
the control of the herpes simplex virus thymidine kinase
promoter (pRL-TK, Promega) was used. However, mea-
suring the luciferase activity of the ﬁreﬂy Photinus pyralis
proved to be unreliable due to partial activation of the
herpes simplex virus thymidine kinase promoter of the
pRL-TK by HMGB1/2 [in agreement with reported eﬀects
of HMGB1 on transactivation of various gene promoters
(8)]. Therefore, the luciferase activity in each cellular
lysates was normalized by determining the protein concen-
trations using the Coomassie G-250 protein-dye assay
(Bio-Rad). The involvement of HMGB1/HMGB2 proteins
on activity of the human topo II  gene promoter was stud-
ied using plasmid -700TOP2B-pGL3 (plasmid pGL3-Basic
containing ﬁreﬂy Photinus pyralis cDNA linked with
sequence  700 to +193nt of the human topo II  gene
promoter; kindly provided by Susan P.C. Colle (Queen’s
University, Cancer Research Institute, Division of Cancer
Biology & Genetics, Kingston, Canada).
Quantitative real-time PCR of TOP2A gene
Total RNA was isolated from 2 10
5 Saos-2 cells by
RNeasy Mini Kit (Qiagen). First-strand cDNA synthesis
was performed using the SuperScript
TM II with
oligo(dT)12–18 primer (Invitrogen). Approximatedly ﬁve-
hundred nanograms of RNA was used for each 20ml
of RT-reaction. Each cDNA sample was analyzed in tri-
plicates using TaqMan Gene Expression Assay (Applied
Biosystems) according to manufacturer’s instructions.
Ampliﬁcation was detected using 7300 Real Time PCR
System (Applied Biosystems). The TaqMan probe used
hybridized between exons 10 and 11 of the TOP2A gene.
Data were analyzed using Sequence Detection System
(SDS) software, version 1.3.1. Results were obtained as
the cycle number when the ﬂuorescence reaches a set
threshold (CT). The relative expression of TOP2A was
quantiﬁed as a percentage of HPRT expression. The dif-
ference in CT values between the TOP2A and HPRT reac-
tions (CT) was converted into relative TOP2A
expression using a formula 2
 C
T   100%.
Chromatin immunoprecipitation (ChIP) assays
Stably transfected Saos-2 cells (control or HMGB1/2
silencing; see shRNA-mediated gene silencing of
HMGB1 and HMGB2 in the Materials and methods sec-
tion) were grown to  80% conﬂuence in 150 cm
2 tissue
culture ﬂasks. Cells were then washed in minimal culture
medium (without FBS and antibiotics) and ﬁxed with 1%
formaldehyde in the same medium on a shaking platform
at room temperature for 10min. Preparation of chromatin
and immunoprecipitation ( 1.5 10
6cells/reaction) was
carried out using the ChiP-IT Enzymatic Express Kit
(Active Motif, Rixensart, Belgium). ChIP-grade NF-YB
rabbit polyclonal antibody (PAb001 from GeneSpin,
Milano, Italy) were at 1mg/reaction. Puriﬁed immunopre-
cipitated DNA was subjected to semi-quantitative PCR
with primers (Fw:5 0-GGTGCCTTTTGAAGCCTCTCT
AG-30,R ev:5 0-GCTCCACTTGAACCTTCCTTTAG
C-30) speciﬁc for a region  215 to  21 of the human
topo II  promoter, generating a 195bp product encom-
passing three NF-Y-binding sites (ICEs1-3). GoTaq Hot
Start DNA polymerase (Promega; 2.5U/100ml reaction)
was used in 1  Green Flexi buﬀer/2mM MgCl2
(Promega). The ampliﬁcation program consisted of dena-
turation at 948C for 2min, followed by 30–34 cycles of
948C for 60s, 588C for 30s and 728C for 30s. As a nega-
tive control, 1mg of control IgG polyclonal antibody (or
1mgo fa-RNA pol II antibody using primers speciﬁc for
human GADPH gene as a positive control) was used
(ChIP-IT Control Kit-Human, Active Motif).
Preparation ofnuclear extract
Nuclear extract was prepared using the published protocol
(25) with some modiﬁcations. Cells were twice washed
with 1  phosphate buﬀered saline (PBS), trypsinized, fol-
lowed by washing with 1  PBS containing 10% FCS.
After ﬁnal wash with PBS, the pellet was re-suspended
in 1ml of ice-cold buﬀer A (10mM HEPES pH 7.9,
10mM KCl, 0.1mM EDTA, 0.1mM EGTA, 1mM
DTT) containing protease inhibitors (1mg/ul aprotinin,
10mg/ul leupeptin, 1mg/ul pepstatin A, 100mg/ul trypsin
inhibitor, 0.1mM TLCK and 20mM benzamidine) and
allowed to swell on ice for 15min. Then 10% Nonidet
P-40 was added to ﬁnal 0.5% and the incubation was
continued for more 5min. Following the incubation, the
cellular suspension was spun down (1200g, 5min), the
nuclei (pellet) were then re-suspended in 1ml of buﬀer A
(lacking Nonidet P-40), and spun-down as above. The
pellet (nuclei) was re-suspended in ice-cold buﬀer B
(20mM HEPES pH 7.9, 0.4M NaCl, 1mM EDTA,
1mM EGTA) containing protease inhibitors, vortexed
Nucleic Acids Research,2009, Vol.37, No. 7 2073for 20s and rocked at 48C for 30min. The suspension was
clariﬁed by centrifugation (15 000 g, 10min) at 48C, and
the clear supernatant containing nuclear extract was
aliquoted, quick frozen in liquid nitrogen and stored at
 708C. For the purpose of the immunoprecipitation, the
nuclear extracts were not frozen and used immediately.
Westernblotting and immunological detection ofproteins
Nuclear extract was prepared from transfected or untrans-
fected cells as above. The protein concentrations were
determined by the Bradford Coomassie G-250 assay
(Bio-Rad) using bovine serum albumin (BSA) as a stan-
dard. Equal amounts of proteins from diﬀerent nuclear
extracts were then separated by SDS–PAGE on SDS/
7.5% or 10%-polyacrylamide gels, and the resolved pro-
teins were transferred onto the PVDF membrane (Bio-
Rad) using a semi-dry blotting apparatus (Biometra).
Detection of human topo IIa was carried out by overnight
incubation of the membrane with monoclonal anti-topo
IIa antibody (1:500 dilution, Topogen), followed by exten-
sive washing the membrane in 1  PBS-T (PBS with 0.1%
Tween-20) and incubation of the membrane with horse-
radish peroxidase conjugated anti-mouse antibody (IgG-
HRP) (1:2000 dilution, GE Healthcare) for 1h. Detection
of HMGB1 or HMGB2 was carried out by overnight
incubation of the membrane with polyclonal a-HMGB1
or HMGB2 antibodies (1:500 dilution, BD Pharmingen or
Aviva), followed by washing the membrane in 1  PBS-T
and incubation of the membrane with goat anti-rabbit
IgG-HRP antibody (1:2000 dilution). Equal loading of
transferred proteins was veriﬁed by detection of actin
using mouse monoclonal Pan-actin antibody (Dako,
1:2000 dilution), followed by incubation of the membrane
with horseradish peroxidase conjugated anti-mouse anti-
body (IgG-HRP) (1:2000 dilution, GE Healthcare) as
detailed above. Visualization of proteins was performed
using West Dura Extended Duration Signal Kit (Pierce).
The intensities of signals were quantiﬁed using Multi
Gauge software of the imaging system LAS-3000 (Fuji).
Pull-downassays
Plasmids encoding wild-type pRb (amino-acid residues
379–928) or Rb (C706Y) mutant (aa residues 379–928)
fused at the N-terminus with glutathione-S-transferase
(GST) were kindly provided by Sybille Mittnacht
(Institute of Cancer Research, Chester Beatty Labs,
London). GST, GST-pRb and GST-HMGB1 were iso-
lated from BL21(DE3) cells as detailed in (20). GST or
GST-tagged pRb (typically 1–2mg) were bound to glu-
tathione Sepharose 4B beads (40ml of 1:1 v/v slurry),
and incubated with puriﬁed HMGB1 from calf thymus
or recombinant rat HMGB1 expressed in E. coli (0.5mg)
in buﬀer PD [20mM Tris–HCl pH 7.6, 0.2M NaCl,
10mM DTT, 0.2% Triton X-100, 0.2% Tween-20, 20%
glycerol (v/v), protease inhibitors: 1mg/ul aprotinin, 10mg/
ul leupeptin, 1mg/ul pepstatin A, 0.1mM TLCK and
20mM benzamidine] by rocking for 2h at 48C. In some
pull-down experiments, GST-tagged HMGB1 or pRb
were bound to glutathione Sepharose beads and rotated
with nuclear extract from Saos-2 cells in the presence or
absence of ethidium bromide (100mg/ml) at 48C for 2–3h.
After extensive washing of the beads in PD buﬀer, the
proteins associated with the beads were separated on
SDS/15% polyacrylamide gels. The proteins were then
transferred onto the PVDF membrane by western blotting
(as above) and incubated with speciﬁc primary antibodies
overnight at room temperature. The polyclonal antibodies
were: a-HMGB1 (1:1000 dilution, BD Pharmingen), a-
pRb (1:500 dilution; C-15, Santa Cruz), and a-NF-YB
(1:1000 dilution; a gift from Roberto Mantovani, Italy).
Following incubation with the primary antibody, the
washed membrane was further incubated with horseradish
peroxidase conjugated anti-rabbit antibody (IgG-HRP)
(1:2000 dilution, GE Healthcare) for 1h. Visualization
of detected proteins was performed as indicated above.
Immunoprecipitation of pRband HMGB1
Nuclear extract from H1299 cells (0.5mg per each experi-
ment) was pre-cleared by rotation with 40ml of protein–
A+G (1:1) agarose beads (1:1 v/v slurry) in 1ml of 1 
ECB buﬀer (0.3M NaCl, 50mM HEPES, pH 7.9, 0.2mM
EDTA, 0. 5mM DTT, 2% Nonidet P-40 plus freshly
added protease and phophatase inhibitors) at 48C for
1h. The beads were removed by centrifugation
(10000 g for 30s), the supernatant (pre-cleared nuclear
extract) was mixed with 10mg of monoclonal anti-
HMGB1 (IgG2a, clone #KS1, Stressgen) or 10mgo f
pre-immune mouse IgG (Sigma), and rotated in 0.5ml
of ECB buﬀer at 48C for 1h. Then, 40ml of pre-cleared
1:1 slurry of protein-A+G agarose beads (pre-incubated
with acetylated bovine serum albumin at 0.1mg/ml in
ECB buﬀer for 1h, followed by extensive washing in
ECB buﬀer) was added and rotation was continued by
more 2h. The beads were then spin down (10000 g for
30s) and extensively washed (ﬁve times) in 1ml of ECB
buﬀer containing 0.5% Nonidet P-40. The washed beads
were then mixed with 20mlo f1 0   loading buﬀer, boiled
for 3–4min and loaded onto SDS/7.5% polyacrylamide
gels. The resolved proteins were transferred onto the
PVDF membrane (Bio-Rad), and the membrane was incu-
bated with polyclonal a-pRb antibody (1:500 dilution;
C-15, Santa-Cruz), followed by washing the membrane
in 1  PBS-T and incubation of the membrane with
horseradish peroxidase conjugated anti-rabbit antibody
(IgG-HRP) (1:2000 dilution, GE Healthcare) for 1h.
Visualization of detected proteins was performed by
ECL detection kit (GE Healthcare).
RESULTS
HMGB1 up-regulates topoIIagenepromoter
To ﬁnd out whether HMGB1 could modulate activity
of the human topo II  gene promoter, luciferase reporter
gene assay was employed by using constructs containing
sequences from bp  617 (or  557) to +90 of the human
topo II  gene promoter (referred as to the full-length
promoter, pTIIa-617 or pTIIa-557). In some cases,
HMGB1 was over-expressed from plasmid encoding the
protein fused with a seven amino acids FLAG-tag at
the N-terminus to distinguish it on western blots from
2074 Nucleic Acids Research, 2009, Vol. 37,No. 7the endogenous HMGB1 (Figure 1A, inset). However, the
luciferase reporter assays using the Flag-tagged and
untagged HMGB1 were indistinguishable (not shown).
As shown in Figure 1, over-expression of HMGB1
resulted in  10–20-fold increase of luciferase activity,
depending on individual transfection experiments, rather
than on slight diﬀerences in the size of the topo II 
promoter constructs used ( 617 or  557bp). These ﬁnd-
ings demonstrated that HMGB1 could up-regulate the
activity of the human topo II  promoter, and that the
activation of the topo II  promoter increased with
the amount of HMGB1 plasmid (Figure 2D; increased
levels of ectopically expressed HMGB1 in nuclear lysates
were conﬁrmed by immunodetection using speciﬁc anti-
HMGB1 antibody, not shown).
The known regulatory elements of the  557 topo II 
gene promoter (pTIIa-557) construct involve ﬁve
inverted CCAAT boxes (referred as to ICEs, Inverted
CCAAT Elements), an Activating TF-binding site
(ATF), and one GC1 box (the second GC box, GC2, is
present only within the  pTIIa-617) and no functional
TATA box (26), Figure 1A. To identify sequences of the
human topo II  promoter involved in HMGB1-mediated
up-regulation of the promoter, Saos-2 cells were co-trans-
fected with the HMGB1 expression plasmid and the luci-
ferase reporter constructs containing varying lengths of
the topo II  gene promoter. Deletions of the sequences
from bp  557 to  142 (encompassing ICE5, ICE4,
ICE3 and ATF) had very little, if any, eﬀect on the ability
of HMGB1 to up-regulate the activity of the promoter
[albeit stepwise deletion of the 50-promoter sequences
from bp  557 to  142 of the full promoter resulted in
up to  20-fold decrease in luciferase activity in the
absence of over-expressed HMGB1, in agreement with
previously published data (24)]. However, truncation of
the topo II  promoter from bp  142 to  90 including
Figure 1. HMGB1 up-regulates activity of human topo II  promoter. (A) Identiﬁcation of elements within human topo II  gene promoter involved in
HMGB1-mediated up-regulation of the promoter. Saos-2 cells were co-transfected with the plasmid constructs containing the –557bp human topo
II  promoter (plasmid pTIIa-557) or one of the truncated topo II  promoter constructs linked to the luciferase reporter gene (as detailed in Materials
and methods section), and plasmid encoding HMGB1 (or empty vector). Inset, over-expression of Flag-tagged HMGB1. Lane 1, cells transfected
with empty vector; lane 2, cells transfected with plasmid encoding Flag-HMGB1. Immunodetection was carried out using speciﬁc a–HMGB1
antibody. (B) Eﬀect of mutation of ICE2 on transactivation of topo II  promoter by HMGB1. Saos-2 cells were co-transfected with the plasmids
harboring the full-length topo II  promoter (plasmids pTIIa-617 or pTIIa-617_ICE2mt) or truncated topo II  promoter (plasmid pTIIa-142 or
pTIIa-142_ICE2mt) containing the wild-type (WT) or mutated ICE2 (ICE2mt), and either empty vector or plasmid encoding HMGB1. Luciferase
activity (referred as to transactivation) in panels (A) and (B) is presented relative to the luciferase activity of the topo II  promoter in cellular lysates
without HMGB1 over-expression (taken as 1). Each transfection experiment was repeated at least ﬁve times with triplicate samples. Values are
presented as the mean   1 SD (error bars) of luciferase activities from triplicate samples in a representative experiment.
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decreased the ability of HMGB1 to up-regulate the
topo II  gene promoter (Figure 1A, pTIIa-142 or
pTIIa-90). A slight activation of the topo II  promoter
lacking all known regulatory sequences (pTIIa-32) by
HMGB1 was to be explained by the reported eﬀect of
the protein on the basal transcription (5,8,27). The
above data suggested the importance of the ICE2 for
the HMGB1-mediated transactivation of the topo II  pro-
moter. The latter conclusion seemed to be conﬁrmed by
mutation of the ICE2 (ATTGG mutated to GTGGA)
within the  142 promoter construct resulting in inability
of HMGB1 to transactivate the  142bp topo II  pro-
moter (pTIIa-142_ICE2mt, Figure 1B, right). However,
while the ICE2 was crucial for the HMGB1-mediated
transactivation of the  142 promoter (Figure 1A), it
was much less important in the context of the full-length
topo II  promoter as revealed by the luciferase gene repor-
ter assay using the  617 promoter construct with mutated
ICE2 (pTIIa-617_ICE2mt, Figure 1B, left). These results
questioned the central role of the ICE2 in the
HMGB1-mediated up-regulation of the human topo II 
promoter, and pointed out the possible importance of
multiple ICEs for the HMGB1-mediated up-regulation
of the topo II  promoter (see Discussion section).
It is generally assumed that HMGB1 could facilitate
binding of a number of transcription factors (such as
steroid hormone receptors, homeitic HOX proteins,
recombination activating gene protein RAG1, octamer
transcription factors Oct-1/Oct-2, human TATA-binding
protein TBP, TFIID and proteins of p53 family) to their
cognate sites by binding to the TFs and delivering them
to the corresponding DNA sequences (5,7,8). NF-Y
(nuclear factor-Y) is a transcription factor comprising
NF-YA, NF-YB, and NF-YC subunits. NF-Y speciﬁcally
recognizes a CCAAT box motif which is found in the
promoter and enhancer regions of many genes, including
the human topo II  gene (26,29). The NF-YA subunit
associates only with the NF-YB:NF-YC heterodimer
creating a functional NF-Y (trimer) CCAAT box DNA-
binding complex. NF-Y binds to the human ICE1-4,
but not to ICE5 (30). The eﬀect of NF-Y on cellular
levels of the human topo IIa (and subsequently on the
regulation of the topo II  gene promoter) is elusive
due to conﬂicting reports (23,31,32). Thus, a simple
explanation for the enhancement of the topo II  pro-
moter activity by HMGB1 could be that HMGB1 could
promote binding of crucial activators, such as NF-Y, to
their DNA-binding sites. Electrophoretic Mobility Shift
Assay (EMSA) was therefore used to determine whether
HMGB1 could enhance binding of NF-Y to short DNA
duplexes containing ICE1, ICE2 or ICE3 sequences
derived from the human topo II  promoter. Addition of
HMGB1 to nuclear lysate from Saos-2 cells could enhance
( 2–3-fold) binding of NF-Y to the ICE2 (Figure 2A),
and also to the ICE1 and ICE3 (data not shown), demon-
strating the ability of HMGB1 to promote NF-Y binding
to various ICEs.
The ability of HMGB1 to promote in vitro binding
of NF-Y to DNA duplexes containing inverted CCAAT
elements (Figure 2A) could indicate that the protein could
modulate NF-Y binding to the human topo II  gene
promoter in vivo. To ﬁnd out whether HMGB1/2 could
aﬀect binding of NF-Y to the topo II  promoter, chroma-
tin immunoprecipitation (ChIP) was used. For this
purpose, control Saos-2 cells and cells with inhibited
HMGB1/2 expression were ﬁxed with formaldehyde,
chromatin sheared by enzymatic digestion and immuno-
precipitated with anti-NF-YB or control antibodies.
Puriﬁed immunoprecipitated DNA was subjected to
semi-quantitative PCR with primers speciﬁc for a region
 215 to  21 of the human topo II  promoter, amplifying
a 195bp product encompassing three NF-Y-binding sites
(ICEs1-3). As shown in Figure 2C, the ChIP analysis
revealed that inhibition of HMGB1/2 expression resulted
in up to  3-fold reduction in NF-Y binding to the topo
II  gene promoter relative to the control cells. These data
provided evidence that HMGB1/2 could modulate NF-Y
binding to the human topo II  promoter in vivo.
To ﬁnd out whether HMGB1 could interact with NF-Y,
in vitro ‘pull-down’ (PD) assay was used. GST or GST-
HMGB1 were immobilized on glutathione Sepharose
beads and incubated with nuclear extract from Saos-2
cells. After extensive washings, the resin-bound proteins
were separated by electrophoresis, followed by western
blotting and immunological detection by anti-NF-YB
antibody. As shown in Figure 2D (top), a signiﬁcant frac-
tion of NF-YB was found to be associated with HMGB1
relative to control GST-bound beads (equal amounts
of GST or GST-HMGB1 immobilized on agarose beads
were veriﬁed by gel electrophoresis, Figure 2D, bottom).
Interaction between HMGB1 and NF-Y was not facili-
tated via DNA as similar results were obtained from PD
assay in the presence of DNA intercalator ethidium
bromide. The above results demonstrated the ability of
HMGB1 to interact with NF-Y, and provided a possible
explanation for the observed HMGB1-mediated enhance-
ment of NF-Y binding to ICEs (Figure 2A), a basis for
understanding of the eﬀect of the protein on the activity
of the topo II  gene promoter (Figure 1).
Intercalating residues ofHMGB1 are required forDNA
bending and up-regulation of topoIIagene promoter
Previous experiments with HMGB proteins from
Sacharomyces cerevisae (NHP6A) and Drosophila melano-
gaster (HMG-D), which are highly related to human
HMGB1 protein, revealed that mutation of DNA inter-
calating residues impaired their DNA-bending properties
(33,34). Using ligase-mediated circularization assay we
have studied whether the intercalating residues (Phe38
of the domain A, and Phe103/Ile122 of the domain B,
Figure 3A) are also required for DNA bending by
human HMGB1. This assay measures the eﬃciency with
which T4 DNA ligase forms minicircles from fragments
of DNA that are shorter than  150bp. In the absence
of internal curvature, the stiﬀness of a short DNA frag-
ment (<150bp) prevents intra-molecular alignment of
its ends so that minicircles are detected only in the pres-
ence a protein that bends DNA.
HMGB1 and individual domains, A and B (Figure 3A),
have been mutated by alanine mutagenesis, and the
2076 Nucleic Acids Research, 2009, Vol. 37,No. 7proteins were expressed in E. coli and puriﬁed to near
homogeneity (Figure 3B). To understand the importance
of individual intercalating amino acids of HMGB1 for
the ability of the protein to bend DNA, single HMG-
boxes, domains A and B, and their mutants were ﬁrst
investigated. In agreement with previous studies
(9,10,18,35,36), the domain B seemed to be more eﬃcient
than the domain A (Figure 3C, lower panel). Mutation of
Phe38 (domain A) or Phe103 (domain B) to alanine
completely abolished the ability of the both single
domains to form DNA minicircles. On the other hand,
mutation of the second intercalating residue of domain
B, Ile122, had only a little eﬀect on the ability of the
domain to bend DNA. Interesting results were obtained
upon mutagenesis of the intercalating residues in the
context of the full-length HMGB1. Whereas mutation
of Phe38 (domain A) exhibited only a little eﬀect on the
ability of the HMGB1 protein to bend DNA, mutation
of Phe103 (domain B) nearly abrogated the ability of
the protein to bend DNA. A complete inhibition of the
Figure 2. HMGB1 interacts with transcription factor NF-Y and modulates its binding to human topo II  promoter. (A) HMGB1 enhances binding
of NF-Y to ICE2. Radioactively labeled 30-bp DNA duplex containing ICE2 was mixed with nuclear extract from Saos-2 cells (lane 1) or nuclear
extract containing increasing concentrations of HMGB1 (1, 2, 3, 4 and 6mM, lanes 2-5, respectively), followed by separation of unbound ICE2 DNA
duplex (free probe) and DNA–protein complexes on 5% non-denaturing polyacrylamide gels (EMSA). The presence of NF-Y within the retarded
complex (arrow) was veriﬁed by super-shifting of the retarded complex (arrow head) with speciﬁc polyclonal antibodies against NF-YB. Speciﬁcity of
NF-Y binding from nuclear extracts to DNA duplexes containing the wild-type ICE2 was also demonstrated by competition experiments with
unlabeled DNA duplexes containing the wild-type or mutated sequence of the ICE2 (not shown). (B) HMGB1 mutant, incapable of DNA bending,
cannot enhance binding of NF-Y to ICEs. EMSA experiment was carried out as in (A). Lane 1, no added HMGB1; lane 2, wild-type HMGB1
(2mM); lane 3, HMGB1(F38A/F103A), 2mM. Arrow indicate the mobility of (NF-Y)–DNA complexes. (C) ChIP assays using anti-NF-YB, control
IgG antibodies or without antibodies were performed using chromatin from Saos-2 cells (control or upon silencing of HMGB1/2 expression, see
Figure 6) as detailed in Materials and methods section. NF-Y binding to the topo II  promoter was detected by gel staining (ethidium bromide) after
PCR ampliﬁcation using primers corresponding to the promoter as described in Materials and methods section. For semi-quantitative PCR,
ampliﬁcation reactions were carried out within the linear range of ampliﬁcation (typically 30–34 cycles). The ChiP data were calculated as a ratio
of PCR signal from ChIPed DNA to the input PCR signal, the ﬁnal data were obtained from comparison of both cell lines (control or HMGB1/2 sil)
and expressed as –fold change. Control, stably transfected Saos-2 cells (vector); HMGB1/2 sil, stably transfected Saos-2 cells with inhibited HMGB1/
2 expression (shRNA-mediated gene silencing of HMGB1/2, Figure 6). The speciﬁc PCR product of 195-bp encompassing ICEs 1-3 is indicated
by an arrow. M, DNA size marker; ICEs, inverted CCAAT elements. (D) Detection of NF-Y binding to HMGB1 or pRb in vitro. (Top) Equal
amounts of GST, GST-HMGB1 or GST-pRb were immobilized on glutathione Sepharose beads and incubated with nuclear extract from Saos-2
cells. After extensive washings, the resin-bound proteins were eluted and separated by SDS-polyacrylamide gel electrophoresis, followed
by W. blotting and immunological detection by anti-NF-YB antibody as detailed in the Material and methods section. EtBr, ethidium bromide.
IN, 25% of the nuclear extract from Saos-2 cells used for the ‘pull-down’ assay (input). (Bottom) GST or GST-tagged proteins immobilized
on agarose beads for the ‘pull-down’assay (Coomassie blue R-250 staining).
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when both intercalating phenylalanine residues, Phe38
and Phe103, had been mutated to alanine (Figure 3C, a
double mutant F38/F103, upper panel). These results
indicated that the domain B could largely substitute for
the DNA-bending potential of the domain A within the
full-length HMGB1, suggesting the major role of the
domain B in mediating DNA bending by HMGB1 [see
also (37)]. In agreement with previous studies (18,36),
the DNA-bending potential of the two HMG-box
domains of HMGB1 was down-regulated by its acidic
C-tail as revealed by enhanced formation of minicircles
by HMGB1 lacking the acidic C-tail (referred as to
HMGB1-C), Figure 3C (upper panel). We have found
that single or multiple alanine mutagenesis of Phe38 and
Phe103 had only a relative small eﬀect on the binding
properties of the full-length HMGB1 protein to linear
DNA [see also (12,34,38,39,56)].
In order to ﬁnd out whether the ability of HMGB1 to
bend DNA was essential for the observed up-regulation of
human topo II  promoter, the impact of over-expression
of either HMGB1 lacking the acidic C-tail (HMGB1-C)
or a double mutant HMGB1(F38A/F103A) has been
investigated. As shown in Figure 3D, over-expression of
HMGB1-C in Saos-2 cells resulted in higher transactiva-
tion of the topo II  promoter than that by the full-length
HMGB1 ( 30-fold and  20-fold, respectively), suggesting
that the acidic C-tail of HMGB1 inhibited the ability of
the protein to activate the topo II  promoter. The higher
transactivation potential of HMGB1-C was consistent
with reported enhanced DNA-bending and -binding prop-
erties of the A+B di-domain (14,18,35,37). The inability
of the HMGB1 mutant to transactivate the topo II 
promoter (Figure 3D) may be related to impaired DNA-
bending properties of the mutant (Figure 3C, top; simi-
lar levels of ectopically expressed HMGB1 and mutants
Figure 3. HMGB1 incapable of DNA bending cannot up-regulate activity of human the topo II  gene promoter. (A) Position of intercalating
residues within the HMGB1 domains A (Phe38) and B (Phe103 and Ile122). (B) Purity of HMGB1, domains A and B, and mutants as revealed
by electrophoresis on an SDS/18% polyacrylamide gel and Coomassie blue R-250 staining. Lane 1, wild-type HMGB1; lane 2, HMGB1(F38A); lane
3, HMGB1(F103A); lane 4, HMGB1(F38A/F103A) [designated as F/F in panels (C) and (D)]; lane 5, HMGB1 lacking the C-tail (HMGB1-C
or A+B di-domain); lane 6, the wild-type domain A; lane 7, domain A (F38A); lane 8, the wild-type domain B; lane 9, domain B (F103A); lane 10,
domain B (F103A/I122A). (C) Eﬀect of mutated intercalating amino acids of HMGB1 or HMGB1 domains A and B on T4 DNA ligase-mediated
DNA cyclization. Ligase-mediated circularization assay was carried out with a
32P-labeled 123-bp DNA duplex, and HMGB1 or HMGB1-C
at concentrations of 0.05, 1 and 1.5mM (left to right, upper panel). For experiments with individual HMGB1 domains, the concentrations of the
domain A or mutants were 1.5, 3 and 6mM, and the concentrations of the domain B or mutants were 0.5, 1 and 1.5mM (left to right, lower panel).
The DNA–protein complexes were ligated with T4 DNA ligase and the deproteinised DNA samples were then separated on 5% non-denaturing
polyacrylamide gels. (D) Transactivation of the topo II  gene promoter by the double-mutant of HMGB1 or HMGB1-C. Plasmids encoding
HMGB1 or mutants were co-transformed with the plasmid pTIIa-617 into the Saos-2 cells, and the luciferase activity (transactivation) was measured
as in Figure 1.
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using speciﬁc antibodies, not shown). The latter idea
was in agreement with the EMSA experiments demon-
strating that HMGB1 incapable of DNA bending
could no longer enhance NF-Y binding to ICEs
(Figure 2B).
Up-regulation oftopo IIagene promoter by HMGB1
is inhibitedby retinoblastoma proteinpRb
In order to ﬁnd out whether HMGB1 modulates activity
of the human topo II  gene promoter in other cell lines
than the Saos-2 (p53
 / /Rb
 / ) cells, comparative trans-
fection experiments were performed with non-small lung
cells carcinoma H1299 (p53
 / /Rb
+/+), human breast
cancer MCF-7 (p53
+/+/Rb
+/+) or human bladder car-
cinoma 5637 (Rb
 / ) cells. While over-expression of
HMGB1 could signiﬁcantly up-regulate the topo II 
promoter both in Saos-2 (Figures 1A and 4A) and 5637
cells (data not shown), over-expression of HMGB1 had
a relatively little (<2–3-fold) eﬀect on the activity of
the  617bp human gene topo II  promoter in MCF-7
or H1299 cells (Figure 4A).
The above results led us to hypothesize that the distinct
eﬀects of HMGB1 on the activity of the topo II  promoter
in diﬀerent cell lines could be explained by the presence of
retinoblastoma susceptibility protein pRb. pRb is a nega-
tive regulator of cellular proliferation and a prototypic
tumor suppressor protein (40). pRb is also required for
eﬃcient activation of cell cycle checkpoints in response
to a variety of DNA lesions, including those induced by
topo IIa poisons (41).
To ﬁnd out whether the absence of functional pRb
could explain why HMGB1 up-regulated the topo II 
promoter much more eﬃciently in pRb-negative as
compared to pRb-positive cells, the impact of HMGB1
over-expression on the activity of the promoter was
studied in the luciferase gene reporter assays using two
diﬀerent approaches: pRb was (i) over-expressed in pRb-
negative Saos-2 cells or (ii) silenced by speciﬁc siRNAs
in pRb-positive H1299 cells. (i) pRb over-expression.
pRb was ectopically expressed in Saos-2 cells and
the luciferase activity was measured. As shown in
Figure 4B, the activity of the topo II  promoter was sig-
niﬁcantly inhibited (up to  3–4-fold) when pRb alone
was over-expressed in Saos-2 cells. When HMGB1
(plasmid-encoded) was over-expressed in the Saos-2 cells
transiently expressing pRb, very little, if any, transactiva-
tion of the topo II  promoter was observed (Figure 4B).
Similar results were obtained when HMGB1 was transi-
ently over-expressed in stable Saos-2 cell derivatives
in which the activity of the Rb gene was controlled by
the tetracycline regulated promoter (data not shown).
These results indicated that ectopically-expressed pRb
could counteract the stimulatory eﬀect of HMGB1 over
the topo II  promoter. (ii) Knock-down of pRb. Silencing
of pRb expression in H1299 cells by speciﬁc siRNAs
(Figure 4C) could signiﬁcantly enhance (up to  3-fold)
the activity of the topo II  promoter in a luciferase gene
reporter assay (Figure 4D), in agreement with previously
published microarray study demonstrating an enhanced
activity of the topo II  gene upon silencing of pRb in
H1299 cells (44). Co-transfection of the cells with silenced
expression of pRb with plasmid encoding HMGB1 could
increase the activity of the promoter in a luciferase gene
reporter assay up to  12-fold (Figure 4D). This was
in contrast to the gene reporter assay using either no
siRNA or control siRNA. While the control siRNA
had no eﬀect on the activity of the topo II  promoter,
co-transfection of these cells with plasmid encoding
HMGB1 could increase the activity of the promoter
only  2-fold (Figure 4D). The above results provided
strong evidence that the up-regulation of the topo II 
promoter by HMGB1 was inhibited by pRb.
pRb protein is functionally inactivated in most human
neoplasms either by direct mutation/deletion (such as
occurs in osteosarcoma, retinoblastoma and small cell
lung carcinoma) or indirectly through altered expression/
activity of upstream regulators (42). pRb is a 928 amino-
acid protein with functionally distinct protein-binding
domains. The A/B pocket (residues 379–792), comprised
of structural domains A and B (Figure 4F, upper panel),
is a hot-spot for mutation in human cancers, and is the
binding site of several viral oncoproteins that inactivate
pRb (42). We have therefore tested whether mutation
of pRb within the A/B pocket (amino-acid 706C ! F)
could abolish the inhibitory eﬀect of pRb on the
HMGB1-mediated up-regulation of the topo II  pro-
moter. As shown in Figure 4B, the transcriptional activity
of the topo II  promoter in Saos-2 cells (in the absence
of over-expressed HMGB1) was very little (if any) aﬀected
by transient expression of the mutant pRb. Similarly,
the mutant pRb could not inhibit the HMGB1-mediated
up-regulation of the activity of the topo II  promoter
in Saos-2 cells (Figure 4B).
A large number of proteins have been demonstrated
to interact with pRb, the majority of which are involved
in transcriptional repression such as histone deacetylases,
components of the mammalian SWI/SNF chromatin-
remodeling complex, histone methyltransferases, hetero-
chromatin proteins, DNA methyltransferases and Poly-
comb group proteins (42). Therefore, we have used PD
assay to study whether pRb could interact with factors
aﬀecting the activity of the human topo II  promoter,
HMGB1 or NF-Y. Previous PD experiments revealed
that HMGB1 and recombinant pRb (unphosphorylated
form) physically interact in free solution (28). In order to
clarify whether HMGB1 could interact with pRb in the
cell, nuclear lysate from pRb-positive H1299 cells was
immunoprecipitated by speciﬁc anti-HMGB1 antibody.
As shown in Figure 4E, a weak band of
co-immunoprecipitated pRb from H1299 lysate with
HMGB1 was apparent, suggesting an interaction of
HMGB1 and pRb in vivo (co-immunoprecipitation of
pRb with HMGB1 was also evident by immunoprecipita-
tion experiments using nuclear lysate from human
erythroleukemia K562 cells, unpublished). pRb was not
co-immunoprecipitated with pre-immune rabbit IgG
(Figure 4E). The electrophoretic mobility of the
co-immunoprecipitated pRb corresponded to the non-
phosphorylated form of the pRb protein [Figure 4E,
see also (43)], although we have not yet determined directly
Nucleic Acids Research,2009, Vol.37, No. 7 2079the phosphorylation state of pRb involved in the interac-
tion with HMGB1.
To ﬁnd out whether the diﬀerent eﬀect of the wild-type
and mutant pRb on the inhibition of the
HMGB1-mediated transactivation of the topo II  pro-
moter (Figure 4B) could be explained by the diﬀerent
interaction of HMGB1 with the wild-type pRb and
mutant pRb, the PD assay was performed. Although
HMGB1 could bind to both the wild-type and mutant
pRb (amino-acid 706C ! Y within the A/B pocket
domain) (Figure 4F), a higher fraction of HMGB1
( 2–3-fold) was associated with the wild-type pRb
Figure 4. HMGB1 up-regulates human topo II  gene promoter in pRb-minus cells. (A) The plasmid pTIIa-617 bearing the human topo II  gene
promoter was co-transfected with either vector (empty bars) or plasmid encoding HMGB1 (black bars) into pRb-negative Saos-2 cells or pRb-
positive H1299 or MCF-7 cells. (B) Up-regulation of activity of human topo II  promoter by HMGB1 is inhibited by wild-type but not mutant pRb.
Saos-2 cells were transiently transfected with the plasmid pTopoIIa-617 and plasmids encoding the wild-type retinoblastoma protein pRb, mutant
pRb (amino-acid 706 C!F) or human HMGB2. Luciferase activity (transactivation) in (A) and (B) was measured and presented as in Figure 1. (C)
Knock-down of pRb in H1299 cells. Nuclear lysates from untransfected cells (lane 1), cells transfected with control siRNA (lane 2) or Rb speciﬁc
siRNAs (lane 3) were resolved by SDS-polyacrylamide gel electrophoresis, and the proteins were then transferred onto the membrane and immu-
nodetected using anti-pRb or anti-actin antibodies. (D) HMGB1 signiﬁcantly stimulates activity of topo II  gene promoter in H1299 cells upon
knock-down of pRb. Control siRNA or Rb speciﬁc siRNAs were transiently co-transfected with plasmid pTIIa-617 and either empty pcDNA3
vector or plasmid encoding HMGB1 into pRb-positive H1299 cells as detailed in the Material and methods section. Luciferase activity (transactiva-
tion) was measured and presented as in Figure 1. (E) Interaction of HMGB1 with pRb in H1299 cells. Cellular lysates from pRb-positive Saos-2 cells
were immunoprecipitated (IP) with monoclonal a-HMGB1 antibody or control (pre-immune) IgG, followed by separation of the precipitated
proteins by SDS-polyacrylamide gel electrophoresis, western blotting and immunodetection with polyclonal anti-pRb antibody as detailed in the
Materials and methods section. (F) Schematic structures of pRb and pRb constructs (upper panel) used for the ‘pull-down’ assay (upper panel). GST
or GST-pRb (wild-type or mutant) were immobilized on glutathione Sepharose beads and incubated with puriﬁed HMGB1 protein. After extensive
washing of the beads, the proteins associated with the beads were resolved electrophoresis, followed by western blotting and immunological detection
by a-HMGB1 antibody as detailed in Material and methods section. Equal amounts of GST-pRb immobilized on beads were conﬁrmed by
immunodetection using anti-pRb (C-15) antibody (lanes 2 and 3). Input, 10% of the HMGB1 used for the pull-down assay.
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immobilized on the glutathione-Sepharose beads were
conﬁrmed by immunodetection using anti-pRb antibody;
lanes 1 and 2 in Figure 4E). Thus, the distinct eﬀects
of HMGB1 on the activity of the topo II  promoter in
pRb-negative or pRb-positive cells (Figure 4A) could not
be explained solely by diﬀerent aﬃnities of the wild-type
and mutant pRb for HMGB1 (Figure 4F).
In order to understand the mechanism of pRb-mediated
inhibition of the activity of the human topo II  promoter,
we have asked whether pRb could interact with NF-Y
in vitro. As shown in Figure 2D (top), incubation of
nuclear lysate from Saos-2 cells with GST-pRb immobi-
lized on glutathione-agarose beads resulted in association
of NF-Y with pRb. Similarly to the NF-Y binding to
HMGB1, the interaction between NF-Y and pRb was
not facilitated via DNA as similar results were obtained
by PD assays in the presence or absence of ethidium
bromide. The detection of pRb-(NF-Y) interactions
prompted us to investigate using EMSA whether pRb
could aﬀect NF-Y binding to the speciﬁc ICE sites
in vitro. Results shown in Figure 5A (lanes 2–5) demon-
strated that binding of NF-Y to a short DNA duplex
containing the ICE2 was visibly compromised by preincu-
bation of nuclear lysate from Saos-2 cells with pRb
(similar results were obtained from EMSA experiments
using the ICE1, not shown). In addition, the
HMGB1-mediated enhancement of NF-Y binding to
the ICE2 was also reduced by preincubation of HMGB1
with pRb (Figure 5A; compare lanes 6, 7 and 8). We have
veriﬁed that the observed reduction of NF-Y binding
by pRb (Figure 5A) was not unspeciﬁc, as titration with
un unrelated protein (GST) in comparable amounts to
pRb had no eﬀect (not shown). The above results sug-
gested that pRb could counteract NF-Y binding to
DNA duplexes containing inverted CCAAT elements.
HMGB-type family consists of three member—
HMGB1, HMGB2 and HMGB3 with an 80% amino-
acid identity among the three proteins. While HMGB1 is
ubiquitously expressed in all mammalian cells ( 10
6 mole-
cules per cell), expression of the other two family members
is more restricted: HMGB2 is widely expressed during
embryonic development, and HMGB3 is only expressed
to a signiﬁcant amount during embryogenesis (5,8). As
both HMGB1 and HMGB2 relatively abundant in
human cells (including Saos-2 cells), we have studied
whether HMGB2 could also up-regulate the topo II 
gene promoter. As shown in Figure 4B, over-expression
of HMGB2 in Saos-2 cells resulted in up to  2-fold higher
transactivation of the topo II  gene promoter relative to
the eﬀect of HMGB1. The latter was not due to diﬀerent
over-expression of HMGB1 and HMGB2 as similar levels
of the two ectopically expressed proteins were immuno-
detected in transfected Saos-2 cells (not shown). Thus,
it is likely that both HMGB1 and HMGB2 could trans-
activate the topo II  gene in the cell.
The two isoforms of topoisomerase II, a and b, exhibit
very similar catalytic activities, but diﬀer in their produc-
tion during the cell cycle (1–4). While the activity of the
human topo II  gene promoter was low in resting cells and
enhanced during proliferation (such as in tumors), the
activity of the human topo II  gene promoter remained
constant throughout the cell cycle (49). Despite a distinct
regulation of the two topo II gene promoters (49), NF-Y
could bind to ICEs of both types of promoters [(49) and
refs therein]. Therefore we were wondering whether
HMGB1 and/or HMGB2 could also modulate trans-
criptional activity of the topo II  promoter. As shown in
Figure 5B, the activity of the topo II  promoter in Saos-2
cells was dose-dependently up-regulated by HMGB1.
Similarly to the topo II  promoter (Figure 4B), the trans-
activation of the topo II  promoter was more prominent
upon over-expression of HMGB2 (Figure 5B). Thus, the
activity of both the topo II  and topo II  promoters could
be up-regulated by HMGB1/2.
HMGB1 and HMGB2 modulate cellular expression
oftopoisomerase IIa
Results of this article indicated that HMGB1 and 2 could
up-regulate the topo II  promoter in the luciferase gene
reporter assay (Figures 1 and 4), suggesting a possibility
that HMGB1 and HMGB2 could aﬀect cellular expres-
sion of topo IIa. To ﬁnd out whether the cellular levels
of topo IIa were aﬀected by HMGB1 and/or HMGB2 in
Saos-2 or H1299 cells, stable cell lines were generated pro-
ducing plasmid-encoded short hairpin RNAs (shRNAs)
speciﬁc for either HMGB1 or HMGB1/HMGB2
mRNAs. In order to verify silencing of HMGB1 and/or
HMGB2 expression, proteins from nuclear lysates were
resolved by electrophoresis, transferred onto the mem-
brane and detected with speciﬁc antibodies recognizing
HMGB1 or HMGB2. As shown in Figure 6, the expres-
sion of HMGB1 was inhibited in H1299 cells by >90% by
Figure 5. (A) pRb can reduce NF-Y binding to ICEs. Radioactively
labeled 30-bp DNA duplex containing the ICE2 was mixed with
nuclear extract from Saos-2 cells (lane 1) or nuclear extract containing
increasing amounts of recombinant His-pRb [lane 2 (0.1mg), lanes 3
and 7 (0.2mg), lanes 4 and 8 (0.4mg)]. In some reactions, HMGB1 was
added [lane 5 (1mM), lanes 6-8 (4mM)]. Unbound DNA duplexes (free
probe) and the DNA–protein complexes were resolved on 5% non-
denaturing polyacrylamide gels (EMSA). (B) Up-regulation of human
topo II  gene promoter by HMGB1 and HMGB2. The plasmid
-700TOP2B-pGL3 bearing the human topo II  gene promoter was
co-transfected with either pGL3 vector (empty bars), plasmid encoding
HMGB1 (black bars) or plasmid encoding HMGB2 (gray bars) into
the Saos-2 cells. Luciferase activity is presented as indicated in Figure 1.
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for HMGB1 and HMGB2 mRNAs (lane 4; H1299). The
latter approach resulted in simultaneous knock-down of
HMGB1 and HMGB2 expression. Similar results were
obtained in Saos-2 cells although silencing of HMGB1
expression was only  60–70% (Figure 6, lane 3; Saos-2).
Control silencing experiments revealed that the levels of
HMGB1 and HMGB2 were unaﬀected in both H1299 and
Saos-2 cells transfected with plasmid producing unrelated
shRNA (Figure 6, lanes 2 as compared to lanes 1 for
untransfected cells).
The cellular levels of topo IIa in cells with silenced
HMGB1 or HMGB1/2 expression were then determined
by western blotting and immunodetection. No signiﬁcant
changes in topo IIa protein levels were observed in pRb-
positive H1299 cells upon silencing of HMGB1 or
HMGB1/2 expression (Figure 6, lanes 3 and 4; H1299),
albeit QRT-PCR analysis revealed minor decrease in topo
II  mRNA levels in H1299 cells with silenced HMGB1/2
expression (not shown). On the other hand, the topo IIa
protein levels in pRb-negative Saos-2 cells with silenced
HMGB1/HMGB2 expression were decreased up to
 3-fold relative to control cells (Figure 6, lane 4; Saos-2).
This ﬁnding was also supported by QRT-PCR analysis
revealing  3-fold decrease in topo II  mRNA levels
in Saos-2 cells with silenced HMGB1/2 expression (data
not shown). The fact that only very little (<20%)
decrease in topo IIa protein levels was observed when
solely HMGB1 expression was silenced in Saos-2 cells
(Figure 6, lane 3; Saos-2) may be related to possible
functional redundancy of these two closely related
HMGB-type proteins (see Discussion section).
In conclusion, we have found that chromosomal pro-
teins HMGB1 and HMGB2 could modulate cellular
expression of topo IIa in cells lacking functional retino-
blastoma gene susceptibility protein pRb by promoting
binding of NF-Y to the topo II  gene promoter. Our ﬁnd-
ings are discussed in the view of reported over-expression
of HMGB1/2 proteins in tumors [(17) and refs therein],
as well as the fact that the Rb gene is deleted/mutated
in >50% human cancers (42).
DISCUSSION
Recently we have reported that chromosomal protein
HMGB1 could stimulate catalytic activities of human
topoisomerase IIa by enhancing DNA binding and cleav-
age by the enzyme (11). Here we report that HMGB1 and
its close relative, HMGB2, could also up-regulate the
activity of the human topo II  gene promoter and cellular
expression of the enzyme. Our results suggest that
HMGB1 and HMGB2 proteins may serve as positive
regulators of the cellular activity of the topo II  gene
(this article) as well as that of the enzyme (11).
HMGB1 and HMGB2 proteins have been implicated in
regulation of chromatin structure and DNA metabolic
processes such as transcription, replication, recombination
and repair (5,8). The lack of HMGB1 in knockout
mice results in death within a few hours after birth due
to ineﬃcient activation of glucocorticoid receptor respon-
sive genes, but HMGB2 knockout mice are viable (15,47).
HMGB2 protein could not substitute in mice for the
loss of HMGB1 (15,47), suggesting that HMGB1 and
HMGB2 proteins may have distinct roles, albeit most
of the reported DNA-binding studies indicated that
the in vitro DNA-binding properties of HMGB1 and
HMGB2 were indistinguishable (5,7,8). Murine and
human cells were viable without functional HMGB1,
indicating that HMGB2 could partially compensate
for the loss of HMGB1 in the cell (48). The possible
functional redundancy of HMGB1 and HMGB2 (at
least in some biological processes) may also explain our
ﬁnding that the double knock-down of HMGB1 and
HMGB2 in pRb-negative cells was necessary in order to
observe a signiﬁcant decrease in cellular levels of topo-
isomerase IIa. However, as we have not succeeded in
silencing of HMGB2 expression only and/or without
concomitant silencing of HMGB1 expression (using vari-
ous shRNA constructs directed against diﬀerent parts
of hHMGB2 mRNA, unpublished results) we could
not determine the exact contribution of the individual
HMGB-type proteins to the cellular expression of
topo IIa.
HMGB1 is an abundant and most mobile nuclear
protein ( 1 10
6 molecules per nucleus), but despite
its abundance the protein may be limiting within cells
as evident from transient over-expression of HMGB1
resulting in transactivation of numerous genes (5,48).
Previous transfection experiments revealed that
HMGB1, but not HMGB1 lacking the acidic C-tail
(HMGB1-C), could stimulate the Gal4VP16-mediated
reporter gene expression (52,53), or the p53-dependent
transactivation of the p53-responsive promoter in H1299
cells (54). Transactivation of the human topoII  gene pro-
moter by HMGB1 did not require the acidic C-tail of
HMGB1 suggesting that the C-tail did not function as
an activator of transcription of the topoII  promoter
(this article). Higher DNA binding and/or bending/loop-
ing by HMGB1-C relative to the full-length HMGB1
Figure 6. Knock-down of HMGB1 and HMGB2 results in inhibition
of topo IIa expression. Nuclear lysates from untransfected (lanes 1) and
mock-transfected (lanes 2) cells, as well as from cells transfected with
plasmids producing shRNAs speciﬁc for HMGB1 (lanes 3, construct
#A) or HMGB1/HMGB2 (lanes 4, construct #B) were resolved on
SDS-polyacrylamide gels and transferred onto the membranes by west-
ern blotting. Proteins were detected by speciﬁc antibodies as detailed in
the Materials and methods section.
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HMGB1 protein activated the topo II  gene promoter
more eﬃciently than the full-length HMGB1. Thus,
shielding of positively charged A+B di-domain of
HMGB1 by the acidic C-tail (13,14,55) may account for
lower ability of the full-length protein to up-regulate the
topo II  gene promoter.
We have demonstrated that intercalating residues of
human HMGB1 (Phe 38 and Phe 103)—that were essen-
tial for the ability of HMGB1 to bend DNA [see also
(12,33,34,56)]—were required for the ability of HMGB1
to enhance binding of NF-Y to ICEs and for the
up-regulation of the topo II  gene promoter (this article).
Interestingly, the intercalating residues of HMGB1 proved
to be dispensable for protein–protein interactions such
as binding of HMGB1 to topoisomerase IIa (11 and
unpublished results) or progesterone receptor (56), as
well as for a speciﬁc binding of progesterone receptor to
its cognate sites (56). The mechanism by which HMGB1/2
proteins stimulate activity of the topo II  promoter
most likely involves enhancement of transcription factors
binding, possibly by pre-bending of the DNA promoter
sequences. Numerous transcription factors have been
reported to interact with HMGB1 and/or HMGB2,
including TBP, Oct and Sp1 (8,27). Binding of NF-Y
to short DNA duplexes containing ICEs1-4-binding sites
(this article), as well as Oct-1/2 (74) and Sp1 (20) to their
DNA cognate sites was enhanced by HMGB1. NF-Y, Sp1
and ICBP90 have previously been shown to be required
for eﬃcient transcription from human topo II  and
topo II  promoters [(23,49,50,51,58) and refs therein).
The ability of HMGB1/2 to enhance NF-Y binding
to the topo II  promoter in vivo was to be explained
by HMGB1-(NF-Y) interactions, and possibly also by
HMGB1-mediated DNA pre-bending of the DNA-
binding sites for NF-Y. The fact that no ternary
HMGB1-(NF-Y)-DNA complex was detected did not
necessarily mean the lack of existence of such a complex.
It is possible that HMGB1 could ‘deliver’ NF-Y to its
DNA-binding site by forming a ternary complex which
is transient and unstable. This idea is in agreement with
previous reports demonstrating the ability of HMGB1
to enhance binding a plethora of sequence-speciﬁc pro-
teins to their cognate DNA sites without formation of
ternary complexes, despite the detection of the corre-
sponding protein–HMGB1 interactions in ‘pull-down’
assays (5,8,11). The existence of interactions of pRb with
NF-Y (and also with HMGB1) may constitute a basis
for understanding of pRb-mediated inhibition of the activ-
ity of the topo II  promoter. The observed decrease in
binding of NF-Y to ICEs by pRb, as well as inhibition
of the ability of HMGB1 to promote binding of NF-Y
binding to ICEs (this report), suggested that pRb could
down-regulate the activity of the topo II  promoter by
preventing NF-Y binding to inverted CCAAT elements.
The exact nature of the interactions involving NF-Y,
HMGB1, pRb (phosphorylated or non-phosphorylated?)
as well as other binding partners on the the topo II 
promoter is unknown. In addition, interaction of
HMGB1 to NF-Y, as well as stimulation of NF-Y binding
to several ICEs in vitro, may also explain our ﬁnding
that sequential deletion of ICEs5-3 from the topo II  pro-
moter had very little eﬀect on the ability of HMGB1 to
up-regulate the promoter. Thus, our results could indicate
possible functional redundancy of ICEs for the activation
of the topo II  promoter by HMGB1.
Results of this article demonstrated that HMGB1 and
HMGB2 proteins could signiﬁcantly up-regulate the
human topo II  gene promoter only in cells lacking
functional retinoblastoma protein pRb. The exact reason
for the inability of HMGB1/2 to signiﬁcantly up-regulate
the activity of the human topo II  gene promoter in
pRb-positive cells is unknown. However, the detectable
(albeit slight) transactivation of the topo II  promoter in
pRb-positive cells could be related to weakening of the
inhibitory eﬀect of pRb on the promoter. This could be
due to HMGB1 binding to pRb which could partially
counteract the inhibitory eﬀect of pRb on NF-Y binding
to ICEs of the topo II  promoter (see also the above
paragraph). On the other hand, the fact that HMGB1
could signiﬁcantly (>10-fold) enhance activity of the
topo II  promoter in Saos-2 cells transiently expressing
mutant pRb (within the A/B pocket) was most likely
related to the inability of the mutant to inhibit the
activity of the topo II  promoter, rather than to the
pRb(mut)-HMGB1 interactions [see also (43)]. The pos-
sibility that the failure of the pRb mutant to inhibit
the activity of the topo II  promoter was related to the
inability of the mutant to interfere with NF-Y binding
to ICEs remains to be investigated.
Previous reports indicated that p53 could also inhibit
activity of the topo II  gene promoter despite the lack
of clear consensus p53-binding sites within the human
topo II  gene promoter (26). This inhibition was explained
as consequence of an interference of p53 with NF-Y bind-
ing to regulatory sequences of the promoter (25,46).
HMGB1 and HMGB2 proteins have previously been
reported to promote binding of p53 (or its close relative,
p73) to their speciﬁc DNA-binding sites by bending and
speciﬁc p53–HMGB1/2 interactions (20,59). Whether
the latter interactions could counteract or even enhance
the reported p53-mediated inhibition of the topo II  gene
promoter activity (20,24,45,60) is unclear. Interestingly,
the catalytic activity of topo IIa was stimulated by p53
(46), albeit by a mechanism diﬀerent from that reported
by HMGB1 (11). Contrary to the action of pRb or
p53, the HMGB-type proteins could both transactivate
the topo II  promoter and stimulate the catalytic activity
of the enzyme (11). A possible mechanism summarizing
interplay of pRb, p53 and HMGB1/2 on the activity of
the topo II  gene and topoisomerase IIa, is outlined in
Figure 7.
The two isoforms of topoisomerase II, a and b, are
encoded by distinct genes on chromosomes 17q21-22
and 3p24, respectively (61,62). While the activity of
the human topo II  gene promoter is low in resting cells
and enhanced during proliferation (such as in tumors), the
activity of the human topo II  gene promoter is constant
throughout the cell cycle (49). Both isoforms diﬀer in
their production during the cell cycle (1–4), but they
exhibit very similar catalytic activities, including the sen-
sitivity to anticancer drugs speciﬁcally targeting topo II.
Nucleic Acids Research,2009, Vol.37, No. 7 2083The latter may be interesting in the view of our ﬁnding
that the activities of both the topo II  and topo II 
gene promoters were up-regulated by HMGB1/2.
Whether the HMGB1/2-mediated activation of the topo
II  gene promoter is also aﬀected by pRb, awaits further
investigation.
Although HMGB1 is expressed throughout the cell
cycle with no signiﬁcant variations (5), the protein is
clearly over-expressed in most human tumors, including
breast carcinoma, melanoma, gastrointestinal stromal
tumors, colon carcinomas and acute myeloblastic leukae-
mia [(5,8,17,63) and references herein]. HMGB1 over-
expression has also been observed upon administration
of hormones (estrogen and/or progesterone), resulting
in increased potency of anticancer drugs cisplatin and
its analogue carboplatin (64). Recently HMGB2 was
also found to be over-expressed in cancer (http://expres
sion.gnf.org/cgi-bin/index.cgi#Q; Gene Expression Atlas,
38065_at).
Most of the human tumors have excess DNA copies of
the TOP2A (encoding topoisomerase IIa) gene [(65,66)
and refs therein], and the TOP2A gene ampliﬁcation
may explain the signiﬁcantly enhanced cellular levels of
topo IIa in tumors (67,68). Topo IIa over-expression has
been reported to be associated with poor cancer-speciﬁc
survival and presence of metastases (66). Up-regulation
of topo IIa could signiﬁcantly aﬀect responsiveness of
tumors to drugs speciﬁcally targeting the enzyme (topo
II poisons) (69,70). The fact that the HMGB1/2-mediated
up-regulation of cellular levels of topo IIa was most
prominent in Rb-minus cells (this article) raises the ques-
tion of a possible relevance of simultaneous HMGB1/2
overexpression and Rb deletions in tumors in respect to
clinical prognosis of patients treated with topo II poisons.
While over-expression of HMGB1/2 proteins could
enhance cellular levels (and/or activity) of topo IIa,
reduced transcriptional activity of HMGB1/2 genes
could diminish the cellular levels (and/or activity) of the
enzyme. Several polymorphisms and/or mutations were
recently identiﬁed in the HMGB1 gene with a potential
regulatory impact on HMGB1 transcription (71). In
this respect, the B-cell chronic lymphocytic leukemia
(B-CLL), a malignant disease with highly variable clinical
course, could be of interest due to deletions of the 13q14
locus (72). About 30–50% of patients with 13q14 deletions
bear Rb deletions (some of them even biallelic, unpub-
lished results). Interestingly, the HMGB1 gene is localized
in the 13q12 locus (5,73). Furthermore, research is neces-
sary to fully understand the involvement of HMGB-type
proteins and their possible interplay with tumor suppres-
sor proteins, pRb and p53, in modulation of cellular
activity of topo IIa.
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